First Disclosures from ACS Chicago 2022
Other articles you may be interested in
June 2024 Molecule Roundup
To choose Molecules of the Month for June, our team reviewed hundreds of molecules from thousands of papers, press releases, conference presentations, and other sources. In this article, you'll find a curated selection of over 60 additional molecules from June that piqued our interest, along with highlights of some of our favorites and explanations of why they're worth keeping an eye on.
October’s Top Pharma & Biotech Deals
Here’s a quick recap of the top business news from October, including major deals, acquisitions, funding rounds, and strategic partnerships. If you missed any updates, here’s your chance to catch up on the most significant developments in the industry.
PRMT5 Target Review: The Next "First-in-Class" Epigenetic Drug?
PRMT5 is an epigenetic “synthetic lethality” target that has attracted much attention among drug hunters. The first generation of PRMT5 inhibitors was limited by systemic toxicities resulting in a cooling of industry interest, until the recent identification of tumor-specific inhibitors. These second-generation compounds target the MTA:PRMT5 complex in MTAP-deleted cancers—15% of all tumors—leading to a revival of the target. Read on to find out which companies are prevailing in the search for a first-in-class PRMT5 inhibitor and how their clinical compounds differentiate.
Key Clinical Compound Updates from September 2024
This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.
Pharmaceutical Business Updates from November 2024
GSK and Roche strengthened their pipelines by forming groundbreaking collaborations that target neurodegenerative diseases and transcription factors, respectively. Meanwhile, Pep2Tango Therapeutics introduced a novel obesity treatment approach, and Amgen faced scrutiny over emerging data on its obesity drug candidate MariTide. This roundup covers the details behind these headlines.